Response to: 'Tofacitinib for the treatment of polyarteritis nodosa: a literature review'. Correspondence on 'Tofacitinib for polyarteritis nodosa: a tailored therapy' by Rimar et al
ANNALS OF THE RHEUMATIC DISEASES(2022)
摘要
We appreciate the interest of Akiyama et al in our report and thank them for the data presented in their letter.1 2 Akiyama et al have presented a thorough literature review and have described a positive and efficacious effect of tocilizumab in 11 cases of refractory polyarteritis nodosa (PAN) described in 6 case series. Indeed, the use of tocilizumab, an interleukin (IL)-6 inhibitor, in vasculitis is gaining evidence in the literature, specifically in large vessel vasculitis including giant cell arteritis and Takayasu arteritis.3 4 Nevertheless, it should be noted that although the …
更多查看译文
关键词
biological therapy,cytokines,systemic vasculitis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要